• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

失活的 Parp2 通过阻断红细胞中复制相关的缺口连接,导致 Tp53 依赖性致死性贫血。

Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.

机构信息

Institute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.

New York University School of Medicine, New York, NY 10016, USA.

出版信息

Mol Cell. 2024 Oct 17;84(20):3916-3931.e7. doi: 10.1016/j.molcel.2024.09.020. Epub 2024 Oct 8.

DOI:10.1016/j.molcel.2024.09.020
PMID:39383878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11615737/
Abstract

Poly (ADP-ribose) polymerase (PARP) 1 and 2 enzymatic inhibitors (PARPi) are promising cancer treatments. But recently, their use has been hindered by unexplained severe anemia and treatment-related leukemia. In addition to enzymatic inhibition, PARPi also trap PARP1 and 2 at DNA lesions. Here we report that, unlike Parp2 mice, which develop normally, mice expressing catalytically inactive Parp2 (E534A and Parp2) succumb to Tp53- and Chk2-dependent erythropoietic failure in utero, mirroring Lig1 mice. While DNA damage mainly activates PARP1, we demonstrate that DNA replication activates PARP2 robustly. PARP2 is selectively recruited and activated by 5'-phosphorylated nicks (5'p-nicks), including those between Okazaki fragments, resolved by ligase 1 (Lig1) and Lig3. Inactive PARP2, but not its active form or absence, impedes Lig1- and Lig3-mediated ligation, causing dose-dependent replication fork collapse, which is detrimental to erythroblasts with ultra-fast forks. This PARylation-dependent structural function of PARP2 at 5'p-nicks explains the detrimental effects of PARP2 inactivation on erythropoiesis, shedding light on PARPi-induced anemia and the selection for TP53/CHK2 loss.

摘要

聚(ADP-核糖)聚合酶(PARP)1 和 2 酶抑制剂(PARPi)是很有前途的癌症治疗方法。但最近,由于不明原因的严重贫血和治疗相关的白血病,它们的应用受到了阻碍。除了酶抑制作用外,PARPi 还能将 PARP1 和 2 捕获到 DNA 损伤处。在这里,我们报告说,与正常发育的 Parp2 小鼠不同,表达无催化活性 Parp2(E534A 和 Parp2)的小鼠在子宫内会因 Tp53 和 Chk2 依赖性红细胞生成失败而死亡,这与 Lig1 小鼠相似。虽然 DNA 损伤主要激活 PARP1,但我们证明 DNA 复制能强烈激活 PARP2。PARP2 被 5'-磷酸化的缺口(5'p-nicks)选择性募集和激活,包括由 Lig1 和 Lig3 解决的那些缺口。无活性的 PARP2,但不是其活性形式或不存在,会阻碍 Lig1 和 Lig3 介导的连接,导致复制叉的剂量依赖性崩溃,这对具有超快叉的红细胞不利。PARP2 在 5'p-nicks 处的这种依赖 PARylation 的结构功能解释了 PARP2 失活对红细胞生成的有害影响,为 PARPi 诱导的贫血和 TP53/CHK2 缺失的选择提供了线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/af7241105045/nihms-2025350-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/f989d0395070/nihms-2025350-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/e8843820f302/nihms-2025350-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/9fbe1ccc9f3d/nihms-2025350-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/d14c00384617/nihms-2025350-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/e98d67f8e524/nihms-2025350-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/000a6582ce01/nihms-2025350-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/af7241105045/nihms-2025350-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/f989d0395070/nihms-2025350-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/e8843820f302/nihms-2025350-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/9fbe1ccc9f3d/nihms-2025350-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/d14c00384617/nihms-2025350-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/e98d67f8e524/nihms-2025350-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/000a6582ce01/nihms-2025350-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852d/11615737/af7241105045/nihms-2025350-f0007.jpg

相似文献

1
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.失活的 Parp2 通过阻断红细胞中复制相关的缺口连接,导致 Tp53 依赖性致死性贫血。
Mol Cell. 2024 Oct 17;84(20):3916-3931.e7. doi: 10.1016/j.molcel.2024.09.020. Epub 2024 Oct 8.
2
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.无活性的聚(ADP - 核糖)聚合酶2(Parp2)通过阻断成红细胞中与复制相关的切口连接,导致p53依赖的致死性贫血。
bioRxiv. 2024 Mar 14:2024.03.12.584665. doi: 10.1101/2024.03.12.584665.
3
The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication.PARP1 和 PARP2 在应对 DNA 损伤和复制过程中的动态变化和调控。
DNA Repair (Amst). 2024 Aug;140:103690. doi: 10.1016/j.dnarep.2024.103690. Epub 2024 May 25.
4
XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites.XRCC1介导PARP1和PAR依赖的PARP2募集至DNA损伤位点。
Nucleic Acids Res. 2025 Feb 8;53(4). doi: 10.1093/nar/gkaf086.
5
Redundant but essential functions of PARP1 and PARP2 in DNA ligase I-independent DNA replication.PARP1 和 PARP2 在 DNA 连接酶 I 独立的 DNA 复制中的冗余但必需的功能。
Nucleic Acids Res. 2024 Sep 23;52(17):10341-10354. doi: 10.1093/nar/gkae672.
6
DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells.高效的DNA双链断裂修复和复制叉稳定性维持需要DNMT1,其缺失会逆转癌细胞对PARP抑制剂的抗性。
Oncogene. 2025 Apr 15. doi: 10.1038/s41388-025-03409-w.
7
Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases.DNA断裂的连接——DNA连接酶与聚(ADP-核糖)聚合酶之间的相互作用
DNA Repair (Amst). 2025 May;149:103843. doi: 10.1016/j.dnarep.2025.103843. Epub 2025 May 2.
8
Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.PARP1和PARP14的新型抑制剂:设计、合成及增强顺铂在癌症治疗中的疗效
Future Med Chem. 2025 Jan;17(1):35-58. doi: 10.1080/17568919.2024.2437972. Epub 2024 Dec 18.
9
Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy.在聚(ADP-核糖)聚合酶(PARP)抑制剂治疗期间减轻T细胞DNA损伤可增强抗肿瘤疗效。
Sci Transl Med. 2025 May 7;17(797):eadr5861. doi: 10.1126/scitranslmed.adr5861.
10
Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer.PARP1和PARP2拷贝数改变在前列腺癌中的预后价值
Lab Invest. 2025 Jun;105(6):104171. doi: 10.1016/j.labinv.2025.104171. Epub 2025 Apr 8.

引用本文的文献

1
NAD Metabolism-Mediated SURF4-STING Axis Enhances T-Cell Anti-Tumor Effects in the Ovarian Cancer Microenvironment.NAD代谢介导的SURF4-STING轴增强卵巢癌微环境中T细胞的抗肿瘤作用。
Cell Death Dis. 2025 Aug 23;16(1):640. doi: 10.1038/s41419-025-07939-9.
2
Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer.聚(ADP-核糖)聚合酶2是一种锌依赖性酶和核小体重组器。
Cell Mol Life Sci. 2025 Jun 30;82(1):267. doi: 10.1007/s00018-025-05785-8.
3
DNA repair and the contribution to chemotherapy resistance.DNA修复及其对化疗耐药性的影响。

本文引用的文献

1
Pas de deux: the coordinated coupling of erythroid differentiation with the cell cycle.双人舞:红细胞分化与细胞周期的协调偶联。
Curr Opin Hematol. 2024 May 1;31(3):96-103. doi: 10.1097/MOH.0000000000000811. Epub 2024 Feb 16.
2
Inactive PARP1 causes embryonic lethality and genome instability in a dominant-negative manner.失活的 PARP1 以显性负性方式导致胚胎致死和基因组不稳定性。
Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2301972120. doi: 10.1073/pnas.2301972120. Epub 2023 Jul 24.
3
ATR kinase supports normal proliferation in the early S phase by preventing replication resource exhaustion.
Genome Med. 2025 May 26;17(1):62. doi: 10.1186/s13073-025-01488-8.
4
Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases.DNA断裂的连接——DNA连接酶与聚(ADP-核糖)聚合酶之间的相互作用
DNA Repair (Amst). 2025 May;149:103843. doi: 10.1016/j.dnarep.2025.103843. Epub 2025 May 2.
5
Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.BRCA1的三十年:机制洞察及其对突变携带者的影响
Cancer Discov. 2025 Mar 3;15(3):461-480. doi: 10.1158/2159-8290.CD-24-1326.
6
ATP-Dependent Chromatin Remodeler CSB Couples DNA Repair Pathways to Transcription with Implications for Cockayne Syndrome and Cancer Therapy.依赖ATP的染色质重塑因子CSB将DNA修复途径与转录相偶联,对科凯恩综合征和癌症治疗具有重要意义。
Cells. 2025 Feb 7;14(4):239. doi: 10.3390/cells14040239.
7
XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites.XRCC1介导PARP1和PAR依赖的PARP2募集至DNA损伤位点。
Nucleic Acids Res. 2025 Feb 8;53(4). doi: 10.1093/nar/gkaf086.
8
'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer.“我的缺口在哪里”:癌症中PARP抑制剂敏感性的潜在机制
Biochem Soc Trans. 2025 Feb 10;53(1):BST20241633. doi: 10.1042/BST20241633.
9
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.聚腺苷二磷酸核糖聚合酶抑制剂与雄激素受体通路抑制剂联合用于转移性去势抵抗性前列腺癌。
Drugs. 2024 Sep;84(9):1093-1109. doi: 10.1007/s40265-024-02071-y. Epub 2024 Jul 26.
ATR 激酶通过防止复制资源枯竭来支持早期 S 期的正常增殖。
Nat Commun. 2023 Jun 19;14(1):3618. doi: 10.1038/s41467-023-39332-5.
4
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA.临床 PARP 抑制剂别构诱导 PARP2 在 DNA 上的滞留。
Sci Adv. 2023 Mar 24;9(12):eadf7175. doi: 10.1126/sciadv.adf7175.
5
Targeting DNA damage response pathways in cancer.靶向癌症中的DNA损伤反应通路。
Nat Rev Cancer. 2023 Feb;23(2):78-94. doi: 10.1038/s41568-022-00535-5. Epub 2022 Dec 5.
6
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.AZD5305 的临床前特征:新一代高选择性 PARP1 抑制剂和捕获剂
Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301.
7
Discovering the drivers of clonal hematopoiesis.发现克隆性造血的驱动因素。
Nat Commun. 2022 Jul 23;13(1):4267. doi: 10.1038/s41467-022-31878-0.
8
DNA single-strand break repair and human genetic disease.DNA 单链断裂修复与人类遗传疾病。
Trends Cell Biol. 2022 Sep;32(9):733-745. doi: 10.1016/j.tcb.2022.04.010. Epub 2022 May 26.
9
PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites.聚腺苷二磷酸核糖聚合酶(PARP)抑制剂捕获 PARP2 并改变 PARP2 在 DNA 损伤部位的募集方式。
Nucleic Acids Res. 2022 Apr 22;50(7):3958-3973. doi: 10.1093/nar/gkac188.
10
PARP inhibition impedes the maturation of nascent DNA strands during DNA replication.PARP 抑制在 DNA 复制过程中阻碍了新生 DNA 链的成熟。
Nat Struct Mol Biol. 2022 Apr;29(4):329-338. doi: 10.1038/s41594-022-00747-1. Epub 2022 Mar 24.